吉因加递交香港主板上市申请

Core Viewpoint - Ginkgo Bioworks (Shaoxing) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, aiming to go public on the main board [1] Company Overview - Ginkgo Bioworks is a leading precision medicine company in China, deeply integrating AI capabilities into various core aspects of the biomarker value chain [1] - The company has developed a multi-omics platform, combining foundational large models with intelligent AI, enabling a full-chain capability from the discovery and validation of multi-omics biomarkers and targets to product development and commercialization [1] Solutions Offered - The company provides three main solutions targeting hospitals, pharmaceutical and biotechnology companies, and medical research institutions: 1. Precision diagnostics 2. Drug development empowerment 3. Clinical research and translation [1] Innovation Framework - Ginkgo Bioworks is committed to accelerating the large-scale clinical application of AI-driven multi-omics technology through an innovative framework that synergizes multi-omics and AI [1] - The goal is to better serve the growing unmet medical needs of the vast patient population in China [1]